Blood Test Offers Earlier Diagnosis of Alzheimer’s Disease

Alzheimer’s disease continues to challenge medical science, affecting millions worldwide. In the quest for earlier and more accurate diagnosis, a new tool, the PrecivityAD test, has emerged.

This blood test may provide answers for patients seeking clarity about their cognitive health after experiencing mild cognitive impairment or other symptoms that may indicate Alzheimer’s or other forms of dementia.

PrecivityAD, developed by C2N Diagnostics, is a biomarker-based blood test that evaluates the likelihood of Alzheimer’s disease in symptomatic individuals who are 55 or older. The test measures the concentrations of amyloid beta proteins and apolipoprotein E (ApoE) in the blood.

These biomarkers are pivotal in identifying the pathological changes associated with Alzheimer’s. C2N has developed two additional tests, PrecivityAD2, which measures levels in a different way, and PrecivityApoE, a genetic test.

By analyzing the ratios and presence of specific isoforms of these proteins, PrecivityAD can predict amyloid plaque presence in the brain, which is a hallmark of Alzheimer’s disease. This test provides a less invasive, more accessible option compared to traditional methods like cerebrospinal fluid analysis or PET scans.

Currently, PrecivityAD is available through health care providers who can order the test for their patients. The process involves a simple blood draw, which is sent to C2N’s CLIA-certified laboratory for analysis. Results are typically available within 10 business days.

The test is not yet covered by Medicare, Medicaid or private insurers. C2N Diagnostics offers a financial assistance program to help mitigate costs for eligible patients.

Benefits of Early Detection

Early detection of Alzheimer’s is crucial for effective management of the disease.

With PrecivityAD, patients can begin treatment plans sooner, potentially slowing the progression of symptoms. This early diagnosis allows patients and their families to make decisions about future care and management options.

The test can help pick good candidates for clinical trials.

Taking one or more of the PrecivityAD tests may not be appropriate in all cases. Patients and caregivers should talk with health care providers about this and other diagnostic options.